Medesis Pharma S.A.
Clinical-stage biotech developing treatments using its AONYS® drug delivery platform.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Manufacturing
Description
Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-20 12:00 |
MEDESIS PHARMA : OUVERTURE D'UNE PROCÉDURE DE LIQUIDATION JUDICIAIRE
|
French | 184.2 KB | ||
| 2024-11-20 17:45 |
MEDESIS PHARMA A FINALISÉ L’ÉTUDE CLINIQUE POUR LE TRAITEMENT DE LA MALADIE D’A…
|
French | 685.0 KB | ||
| 2024-11-20 17:45 |
MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'…
|
English | 614.2 KB | ||
| 2024-11-14 18:00 |
MEDESIS PHARMA : CONVERSION DE LA PROCÉDURE DE SAUVEGARDE EN REDRESSEMENT JUDIC…
|
French | 314.0 KB | ||
| 2024-11-12 18:00 |
MEDESIS PHARMA : Rapport Financier Semestriel 2024
|
French | 2.5 MB | ||
| 2024-11-12 18:00 |
MEDESIS PHARMA : Activités & résultats du 1er semestre 2024
|
French | 1.1 MB | ||
| 2024-10-08 08:00 |
Participation de MEDESIS PHARMA au Congrès mondial pour les études cliniques s…
|
French | 487.6 KB | ||
| 2024-10-08 08:00 |
MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alz…
|
English | 461.5 KB | ||
| 2024-09-20 08:00 |
MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai cliniq…
|
French | 236.8 KB | ||
| 2024-09-04 17:45 |
MEDESIS PHARMA : MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES À L’ASSEMBLÉE G…
|
French | 274.7 KB | ||
| 2024-07-15 08:00 |
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2023
|
French | 828.9 KB | ||
| 2024-07-15 08:00 |
MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
|
English | 737.2 KB | ||
| 2024-06-03 18:00 |
MEDESIS PHARMA : Obtention d’un financement pour poursuivre l'analyse des résul…
|
French | 498.8 KB | ||
| 2024-03-19 18:01 |
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
|
English | 264.7 KB | ||
| 2024-03-19 18:01 |
Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.
|
French | 302.0 KB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Medesis Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
Peer Companies
